Healthcare / Drug Manufacturers - Specialty & GenericBSE
$12.90
+0.27 (+2.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-67.6M · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$319M
P/E
14.0x
↓EV/EBITDA
9.8x
↓ROE
1.1%
↑Gross Margin
30.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.3%
FCF CAGR
—
FCF margin
-8.8%
FCF / Net income
-5.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $750.6M · net income $11.6M · FCF $-65.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $750.6M | $750.6M | $597.3M | $450.2M | $331.7M |
| Net Income | $11.6M | $11.6M | $14.9M | $3.1M | $3.2M |
| EBITDA | $31.4M | $31.4M | $37.4M | $19.5M | $21.3M |
| EPS | 0.45 | 0.45 | 0.80 | 0.24 | 0.21 |
| Gross Margin | 30.0% | 30.0% | 31.9% | 39.1% | 52.2% |
| Operating Margin | 2.3% | 2.3% | 3.8% | 1.3% | 12.5% |
| Net Margin | 1.5% | 1.5% | 2.5% | 0.7% | 1.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Current Ratio | 3.81 | 3.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-65.7M | $-65.7M | $-128.6M | $-67.6M | $-6.8M |
| Returns | |||||
| ROE | 1.1% | 1.1% | 1.5% | 0.4% | 0.4% |
| Valuation | |||||
| P/E | 14.01 | 14.01 | 35.74 | 125.00 | 187.86 |
| EV/EBITDA | 9.80 | 9.80 | 14.05 | 19.70 | 28.47 |
| P/B | 0.31 | 0.31 | 0.55 | 0.47 | 0.81 |
| Growth & Yield | |||||
| Revenue Growth | 25.7% | 25.7% | 32.7% | 35.7% | — |
| EPS Growth | -43.8% | -43.8% | 233.3% | 14.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.5%
EPS terminal req.
$1.14
Spread vs growth
-80.3%
5Y implied EPS CAGR
25.2%
EPS terminal req.
$1.39
Spread vs growth
-69.0%
10Y implied EPS CAGR
17.4%
EPS terminal req.
$2.23
Spread vs growth
-61.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.4%
Start / end P/E
27.0x → 28.6x
EPS bridge
0.80 → 0.45
Residual
-2.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.